Head-To-Head Survey: Alpha Teknova (TKNO) vs. The Competition

Alpha Teknova (NASDAQ:TKNO) is one of 109 publicly-traded companies in the “Life Sciences Tools & Services” industry, but how does it compare to its peers? We will compare Alpha Teknova to similar companies based on the strength of its earnings, valuation, institutional ownership, dividends, analyst recommendations, risk and profitability.

Insider and Institutional Ownership

13.8% of Alpha Teknova shares are held by institutional investors. Comparatively, 54.2% of shares of all “Life Sciences Tools & Services” companies are held by institutional investors. 13.2% of Alpha Teknova shares are held by insiders. Comparatively, 14.8% of shares of all “Life Sciences Tools & Services” companies are held by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock will outperform the market over the long term.

Earnings & Valuation

This table compares Alpha Teknova and its peers gross revenue, earnings per share (EPS) and valuation.

	Gross Revenue	Net Income	Price/Earnings Ratio
Alpha Teknova	$45.95 million	-$17.26 million	-27.59
Alpha Teknova Competitors	$2.33 billion	$55.11 billion	-8.25

Alpha Teknova’s peers have higher revenue and earnings than Alpha Teknova. Alpha Teknova is trading at a lower price-to-earnings ratio than its peers, indicating that it is currently more affordable than other companies in its industry.

Profitability

This table compares Alpha Teknova and its peers’ net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Alpha Teknova	-34.76%	-24.41%	-16.07%
Alpha Teknova Competitors	-538.54%	-166.23%	-13.47%

Risk & Volatility

Alpha Teknova has a beta of 0.96, indicating that its stock price is 4% less volatile than the S&P 500. Comparatively, Alpha Teknova’s peers have a beta of 0.94, indicating that their average stock price is 6% less volatile than the S&P 500.

Analyst Ratings

This is a summary of current ratings and recommmendations for Alpha Teknova and its peers, as reported by MarketBeat.com.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Alpha Teknova	1	1	4	0	2.50
Alpha Teknova Competitors	951	3172	5504	178	2.50

Alpha Teknova currently has a consensus target price of $8.75, suggesting a potential upside of 9.38%. As a group, “Life Sciences Tools & Services” companies have a potential downside of 3.07%. Given Alpha Teknova’s higher possible upside, equities analysts plainly believe Alpha Teknova is more favorable than its peers.

Summary

Alpha Teknova peers beat Alpha Teknova on 8 of the 13 factors compared.

About Alpha Teknova

Alpha Teknova, Inc. produces critical reagents for the research, discovery, development, and commercialization of novel therapies, vaccines, and molecular diagnostics in the United States and internationally. The company offers pre-poured media plates for cell growth and cloning; liquid cell culture media and supplements for cellular expansion; and molecular biology reagents for sample manipulation, resuspension, and purification. It provides lab essentials which provides chemical formulations for use in biological research and drug discovery; and clinical solutions, a custom product used in the development and production of protein therapies, gene therapies, mRNA vaccines, and diagnostic kits. The company serves its products to life sciences market, including pharmaceutical and biotechnology companies, contract development and manufacturing organizations, in vitro diagnostic franchises, as well as academic and government research institutions. Alpha Teknova, Inc. was founded in 1996 and is headquartered in Hollister, California.